Peripheral neuropathies induced by BRAF+MEK inhibitor combinations: a real-world study based on FAERS database 2011–2022
According to our findings, BRAFi+MEKi-associated PN tends to occur several months after initiation and may lead to serious outcomes. Male sex is more likely to be a risk factor associated with PN. Prompt identification and intervention for BRAFi+MEKi-associated PN are crucial, and additional fundamental research is required to validate the underlying mechanism as observed in our study.
Authors
- Ling Su (ORCID: https://orcid.org/0000-0001-7008-0550)
- Yuting Wang (ORCID: https://orcid.org/0000-0001-6176-2381)
- Jingping Zheng (ORCID: https://orcid.org/0000-0002-9770-4308)
- Zhenpo Zhang (ORCID: https://orcid.org/0009-0006-8175-4972)
- Haiyan Mai (ORCID: https://orcid.org/0009-0007-7022-173X)
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1080/14740338.2025.2529428
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00